Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current developments in adenovirus-based cancer gene therapy.

Daniel T Rein1, M Breidenbach, David T Curiel

  • 1University of Düsseldorf Medical Center, Department of Obstetrics and Gynecology, Düsseldorf, Germany.

Future Oncology (London, England)
|March 25, 2006
PubMed
Summary

Adenovirus (Ad)-based cancer gene therapy shows promise for resistant cancers. New strategies improve tumor targeting and infection, overcoming limitations of early Ad therapies for better efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intranasal boosting induces variant-specific responses in SARS-CoV-2 vaccine-imprinted mice.

Nature communications·2026
Same author

Search for Double Beta Decays of ^{134}Xe with EXO-200 Phase II.

Physical review letters·2026
Same author

AAV vectors for cancer gene therapy.

Advances in cancer research·2026
Same author

Neural stem cell delivery of oncolytic CRAd-S-pk7 immunotherapy for stage 3 ovarian cancer: Dose-regimen studies.

Molecular therapy. Oncology·2026
Same author

Long-acting interleukin-7 improves the efficacy of oncolytic viral therapy in glioblastoma.

Nature communications·2026
Same author

An intranasal adenoviral-vectored vaccine protects against highly pathogenic avian influenza H5N1 in naive and antigen-experienced animals.

Cell reports. Medicine·2026

Area of Science:

  • Oncolytic virology
  • Cancer gene therapy
  • Molecular virology

Background:

  • Adenovirus (Ad)-based cancer gene therapy offers a novel approach for treating drug-resistant cancers.
  • Early nonreplicative Ad vectors showed limited efficacy due to low infectivity, particularly with Ad serotype 5 (Ad5) linked to coxsackie-Ad receptor (CAR) expression variability.
  • Conditionally replicating Ads (CRAds) were developed to enhance tumor-specific replication and oncolysis.

Purpose of the Study:

  • To review recent advancements in Ad-based cancer gene therapy.
  • To highlight strategies for overcoming CAR-dependent infectivity limitations.
  • To discuss novel engineering techniques for improved tumor targeting and restricted transgene expression.

Main Methods:

  • Development of conditionally replicating Ads (CRAds) for tumor-specific replication.

Related Experiment Videos

  • Engineering of Ad capsids to enhance tumor targeting.
  • Application of molecular strategies for CAR-independent Ad infection.
  • Development of targeting techniques to restrict transgene expression to cancer cells.

    • Main Results:

    • CRAds enable tumor-specific replication, oncolysis, and progeny virus release.
    • Molecular strategies are being developed to create CAR-independent oncolytic Ads.
    • Novel Ad capsid engineering improves tumor targeting efficiency.
    • Targeting techniques aim to restrict transgene expression specifically within cancer cells.

    Conclusions:

    • Recent developments focus on engineering Ad vectors for enhanced tumor targeting and overcoming CAR-dependent infectivity.
    • Molecular strategies and capsid modifications are crucial for improving the efficacy of Ad-based cancer gene therapy.
    • Future Ad-based therapies aim for greater specificity and effectiveness against resistant cancers.